TITLE

Merck Confirms 2012 Full-Year Guidance

PUB. DATE
March 2012
SOURCE
Biomedical Market Newsletter;3/7/2012, Vol. 21, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on expectations of the company Merck on non GAAP earnings per share (EPS) and GAAP EPS for full-year 2012, including research and development expense but excluding acquisition related costs and restructuring programs costs. The company expects nonGAAP EPS to be in between 3.75-3.85 dollars, and GAAP EPS range to be 2.04 dollar to 2.30 dollars.
ACCESSION #
75436115

 

Related Articles

  • Is It Time to Ditch EPS As a Measure of Real Value? Dobbs, Richard; Nand, Billy; Rehm, Werner // Mergers & Acquisitions: The Dealermaker's Journal;May2005, Vol. 40 Issue 5, p24 

    The article focuses on measuring the value of earnings per share (EPS). The dilutive effect of acquisitions involving the issuing of shares can be corrected by assessing the impact of acquisitions on EPS rather that on total net income. The accounting methodology International Financial Reports...

  • Sizing Up the 'What's Next?' for EMC, Data Domain.  // Channel Insider;7/10/2009, p1 

    The article reports on the acquisition of Data Domain Inc. by EMC Corp. to block its rival NetApp Inc. EMC says that it passed its rival NetApp's thunder when it entered into a definintive agreement with Data Domain in a cash tender of 33.50 dollars per share, or around 2.1 billion dollars....

  • Bristol-Myers Squibb's 2nd Quarter Highlighted by the Planned Strategic Acquisition of Amylin Pharmaceuticals and Important Clinical Data in Immuno- Oncology.  // Biomedical Market Newsletter;7/26/2012, Vol. 21, p1 

    The article informs that Bristol-Myers Squibb Co. has reported results for the 2nd quarter of 2012. It also highlights the acquisition of Amylin Pharmaceuticals Inc. and the presentation of clinical data from the company's immuno-oncology pipeline. It also informs that the company has adjusted...

  • SFAS No. 128: A first look at the new EPS standard. Bloom, Robert; Cenker, William J. // Ohio CPA Journal;Jul-Sept97, Vol. 56 Issue 3, p33 

    Discusses the major requirements of the Statement of Financial Accounting Standards No. 128 (SFAS No. 128) issued by the Financial Accounting Standards Board, `Earnings per Share.' Elements of earnings per share (EPS) calculations and disclosures; Computation of basic EPS; Call options and...

  • Earnings Per Share.  // Accountancy;Apr1971, Vol. 82 Issue 932, p219 

    Presents a proposed statement of standard accounting on the disclosure of earnings per share. Requirement of financial reporting; Guidelines for the determination of earnings per share; Basis for calculating earnings per share.

  • 'New' Five-Division Merck Still Eager for Biotech Alliances. Young, Donna // BioWorld Today;9/1/2009, Vol. 20 Issue 168, p1 

    The article focuses on plans by Merck & Co. Inc to partner with biotechnology companies after it finalized its merger with Schering-Plough Corp. The combined entity would establish the Merck BioVentures division, which was created in December 2008 to pursue innovative and follow-on biologics...

  • SPECIALITIES ROUNDUP. Tong, Alfred // Asian Chemical News;4/5/2004, Vol. 10 Issue 440, p8 

    Presents updates on the chemical industry as of April 5, 2004. Company that will be acquired by biotechnology company Amgen in California; Number of jobs that will be affected by the plan of Merck to reorganize its business in France; Forecast for the U.S. electronic chemicals markets in 2009.

  • MERCK'S FIRST QTR. EARNINGS PER SHARE INCREASE 17%.  // Biotech Financial Reports;Jun2000, p3 

    Reports the financial performance of Merck and Co. Inc. for the first quarter of 2000 in New Jersey. Percentage increase in the earnings per share and net income of the company; Products contributing to the sales growth for the quarter; Introduction of prescription savings plan called...

  • Merck seeks way to stem sales slide. Weinstein, Deborah // Medical Marketing & Media;Dec2013, Vol. 48 Issue 12, p17 

    The article reports on the decline of earnings of pharmaceutical company Merck & Co. Inc. for the third quarter of 2013, with sales were $11 billion, a decline of almost 4% from the third quarter of 2012.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics